Outcomes better for Black men compared with White men in clinical trials of definitive radiotherapy for localized prostate cancer <\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Jan. 12, 2022 (HealthDay News) — Among men with localized prostate cancer enrolled in clinical trials for definitive radiotherapy, Black men have better outcomes than White men, according to a review published online Dec. 29 in JAMA Network Open<\/em>.<\/p>\n Ting Martin Ma, M.D., Ph.D., from University of California in Los Angeles, and colleagues conducted a systematic literature review and meta-analysis of data from randomized clinical trials of definitive radiotherapy for patients with localized prostate cancer. The selected studies enrolled a substantial number of Black men and reported on treatment-specific and overall outcomes.<\/p>\n Based on seven clinical trials (8,814 patients; 18.5 percent Black), the researchers found that at enrollment, Black men were more likely to have high-risk disease features. However, Black men were less likely to experience biochemical recurrence (subdistribution hazard ratio [sHR], 0.88; 95 percent confidence interval [CI], 0.58 to 0.91), distant metastasis (sHR, 0.72; 95 percent CI, 0.58 to 0.91), or prostate cancer-specific mortality (sHR, 0.72; 95 percent CI, 0.54 to 0.97). There were no significant differences noted in all-cause mortality (HR, 0.99; 95 percent CI, 0.92 to 1.07). Black race remained significantly associated with improved biochemical recurrence (adjusted sHR, 0.79; 95 percent CI, 0.72 to 0.88; P < 0.001), distant metastasis (adjusted sHR, 0.69; 95 percent CI, 0.55 to 0.87; P = 0.002), and prostate cancer-specific mortality (adjusted sHR, 0.68; 95 percent CI, 0.50 to 0.93; P = 0.01) in an adjusted analysis.<\/p>\n “The findings of this meta-analysis noted that Black men enrolled in randomized clinical trials presented with more aggressive disease features but had better treatment and disease-specific outcomes with radiotherapy-based therapy compared with White men, suggesting other important factors associated with outcome, such as access to care, as sources of disparity,” the authors write.<\/p>\n Several authors disclosed financial ties to pharmaceutical and medical-related companies. <\/p>\n Abstract\/Full Text<\/a><\/p>\n